Published in Proc Natl Acad Sci U S A on April 23, 2002
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev (2006) 2.74
Specialized roles for cysteine cathepsins in health and disease. J Clin Invest (2010) 2.69
Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci U S A (2003) 1.83
Proteases for processing proneuropeptides into peptide neurotransmitters and hormones. Annu Rev Pharmacol Toxicol (2008) 1.82
Genes and environment: novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure. J Hypertens (2012) 1.41
Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest (2003) 1.33
Cathepsin L stabilizes the histone modification landscape on the Y chromosome and pericentromeric heterochromatin. Mol Cell Biol (2006) 1.22
Cathepsins mediate tumor metastasis. World J Biol Chem (2013) 1.07
Transcription factor MITF regulates cardiac growth and hypertrophy. J Clin Invest (2006) 1.07
Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. J Exp Med (2007) 1.06
Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides. Endocrinology (2009) 1.01
Cathepsin-L ameliorates cardiac hypertrophy through activation of the autophagy-lysosomal dependent protein processing pathways. J Am Heart Assoc (2013) 1.00
Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol (2008) 0.99
Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev (2012) 0.95
Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol (2009) 0.94
Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol (2008) 0.94
Autophagy and the ubiquitin-proteasome system in cardiac dysfunction. Panminerva Med (2010) 0.92
Age and gender related reference values for transthoracic Doppler-echocardiography in the anesthetized CD1 mouse. Int J Cardiovasc Imaging (2006) 0.92
Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction. Cardiovasc Res (2013) 0.87
Protein misfolding and cardiac disease: establishing cause and effect. Autophagy (2008) 0.87
Protective role of cathepsin L in mouse skin carcinogenesis. Mol Carcinog (2011) 0.86
Do molecular signals from the conceptus influence endometrium decidualization in rodents? J Exp Zool B Mol Dev Evol (2009) 0.86
ABCA5 resides in lysosomes, and ABCA5 knockout mice develop lysosomal disease-like symptoms. Mol Cell Biol (2005) 0.86
Insights into novel cellular injury mechanisms by gene expression profiling in nephropathic cystinosis. J Inherit Metab Dis (2010) 0.85
Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. Am J Cardiol (2008) 0.83
Mitophagy and heart failure. J Mol Med (Berl) (2015) 0.82
Cathepsin-L, a key molecule in the pathogenesis of drug-induced and I-cell disease-mediated gingival overgrowth: a study with cathepsin-L-deficient mice. Am J Pathol (2002) 0.80
Cysteinyl cathepsins: multifunctional enzymes in cardiovascular disease. Chonnam Med J (2012) 0.80
Cathepsin L targeting in cancer treatment. Pharmacol Ther (2015) 0.79
Deficiency for the cysteine protease cathepsin L impairs Myc-induced tumorigenesis in a mouse model of pancreatic neuroendocrine cancer. PLoS One (2015) 0.77
B-cell lymphopoiesis is regulated by cathepsin L. PLoS One (2013) 0.76
Lysosomal protein turnover contributes to the acquisition of TGFβ-1 induced invasive properties of mammary cancer cells. Mol Cancer (2015) 0.76
Cathepsin L acutely alters microvessel integrity within the neurovascular unit during focal cerebral ischemia. J Cereb Blood Flow Metab (2015) 0.75
Cathepsin L activity correlates with proteinuria in chronic kidney disease in humans. Int Urol Nephrol (2017) 0.75
The biogenesis of lysosomes. Annu Rev Cell Biol (1989) 10.73
The efficiency of systematic sampling in stereology and its prediction. J Microsc (1987) 10.24
Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature (2000) 6.34
Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature (2000) 5.71
The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell (2001) 5.35
Stereology of arbitrary particles. A review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsc (1986) 5.13
MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell (1997) 4.67
Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med (2000) 4.30
Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science (1998) 3.98
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest (2002) 3.33
Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science (1998) 3.22
Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation (1998) 3.14
Emerging roles for cysteine proteases in human biology. Annu Rev Physiol (1997) 3.05
Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91
Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta (2000) 2.76
Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation (1999) 2.59
Dilated cardiomyopathy and atrioventricular conduction blocks induced by heart-specific inactivation of mitochondrial DNA gene expression. Nat Genet (1999) 2.57
Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell (1999) 2.57
Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation (2000) 2.32
X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation (1993) 2.30
Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J (2000) 2.24
Recent stereological methods for cell biology: a brief survey. Am J Physiol (1990) 2.10
Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J (2000) 2.09
Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest (1998) 2.00
Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J Clin Invest (2000) 1.91
Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. Circulation (1999) 1.73
MEROPS: the peptidase database. Nucleic Acids Res (2000) 1.69
Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice. J Clin Invest (1998) 1.59
Use of telemetry to record electrocardiogram and heart rate in freely moving mice. J Pharmacol Toxicol Methods (1993) 1.56
Accuracy of echocardiographic estimates of left ventricular mass in mice. Am J Physiol Heart Circ Physiol (2001) 1.55
Proteases involved in MHC class II antigen presentation. Immunol Rev (1999) 1.54
The inhibition of macrophage protein turnover by a selective inhibitor of thiol proteinases. Biochem J (1980) 1.50
Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy. Proc Natl Acad Sci U S A (2000) 1.40
A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen. Biochem J (1988) 1.29
Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the alpha cardiac myosin heavy chain gene. J Clin Invest (1999) 1.28
Cardiac compartment-specific overexpression of a modified retinoic acid receptor produces dilated cardiomyopathy and congestive heart failure in transgenic mice. J Clin Invest (1997) 1.23
Metabolic cardiomyopathies. Int J Exp Pathol (2000) 1.19
Vacuolar/lysosomal proteolysis: proteases, substrates, mechanisms. Curr Opin Cell Biol (1993) 1.09
Linkage of familial dilated cardiomyopathy to chromosome 9. Heart Muscle Disease Study Group. Am J Hum Genet (1995) 1.09
Cellular proteolysis. An overview. Ann N Y Acad Sci (1992) 1.07
Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells. Eur J Cancer (2000) 1.00
Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem (1998) 0.99
Cell degeneration in alopecia areata. An ultrastructural study. Am J Dermatopathol (1991) 0.88
Nonischemic heart failure: epidemiology, pathophysiology, and progression of disease. J Cardiovasc Pharmacol (1999) 0.84
Matrix metalloproteinases: not-so-innocent bystanders in heart failure. J Clin Invest (2000) 0.78
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol (2008) 10.39
Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med (2015) 6.68
Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med (2007) 6.23
Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev (2004) 5.89
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet (2004) 3.88
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J (2004) 2.78
Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation (2004) 2.77
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J Biol Chem (2002) 2.76
Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation (2006) 2.76
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev (2006) 2.74
Specialized roles for cysteine cathepsins in health and disease. J Clin Invest (2010) 2.69
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) (2004) 2.68
Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol (2002) 2.58
Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am J Pathol (2005) 2.56
The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace (2009) 2.52
Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet (2002) 2.49
Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace (2012) 2.30
Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des (2007) 2.26
Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: different incidences in familial and sporadic disease. Hum Mutat (2003) 2.24
Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res (2006) 2.20
Atrial fibrillation-induced cardiac troponin I release. Int J Cardiol (2013) 2.16
Pacemaker channel dysfunction in a patient with sinus node disease. J Clin Invest (2003) 2.14
Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol (2004) 2.12
The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J (2003) 2.10
Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J (2008) 2.09
Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. Eur Heart J (2007) 1.98
Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias in patients with long QT syndrome. J Cardiovasc Electrophysiol (2003) 1.98
Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). J Am Coll Cardiol (2011) 1.91
Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. Cardiovasc Res (2003) 1.91
Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90
FGF4, a direct target of LEF1 and Wnt signaling, can rescue the arrest of tooth organogenesis in Lef1(-/-) mice. Genes Dev (2002) 1.88
Hair follicle pigmentation. J Invest Dermatol (2005) 1.84
Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci U S A (2003) 1.83
Chronic kidney disease in patients with chronic heart failure--impact on intracardiac conduction, diastolic function and prognosis. Int J Cardiol (2006) 1.80
Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. J Cardiovasc Electrophysiol (2007) 1.79
Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation (2005) 1.78
Key role of CRF in the skin stress response system. Endocr Rev (2013) 1.77
The cutaneous serotoninergic/melatoninergic system: securing a place under the sun. FASEB J (2005) 1.77
The NK receptor KLRG1 is dispensable for virus-induced NK and CD8+ T-cell differentiation and function in vivo. Eur J Immunol (2010) 1.72
Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med (2005) 1.69
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. J Cardiovasc Electrophysiol (2007) 1.68
Cardiac autonomic dysfunction in Brugada syndrome. Circulation (2002) 1.68
Further exploring the brain-skin connection: stress worsens dermatitis via substance P-dependent neurogenic inflammation in mice. J Invest Dermatol (2007) 1.67
Regulation of human epidermal melanocyte biology by beta-endorphin. J Invest Dermatol (2003) 1.66
NF-kappaB transmits Eda A1/EdaR signalling to activate Shh and cyclin D1 expression, and controls post-initiation hair placode down growth. Development (2006) 1.66
Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol (2011) 1.65
Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail (2008) 1.64
Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace (2013) 1.63
Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors. Cardiovasc Res (2004) 1.60
Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A (2010) 1.60
Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm (2010) 1.59
Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut (2011) 1.58
Impaired myocardial perfusion and perfusion reserve associated with increased coronary resistance in persistent idiopathic atrial fibrillation. Eur Heart J (2007) 1.58
Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort. Europace (2011) 1.57
Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. Eur Heart J (2008) 1.57
"Largest amplitude ablation" is the optimal approach for typical atrial flutter ablation: a subanalysis from the AURUM 8 study. J Cardiovasc Electrophysiol (2012) 1.56
Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging (2006) 1.55
Diastolic isthmus length and 'vertical' isthmus angulation identify patients with difficult catheter ablation of typical atrial flutter: a pre-procedural MRI study. Europace (2008) 1.54
Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure. Heart Rhythm (2011) 1.54
Gold vs. platinum-iridium tip catheter for cavotricuspid isthmus ablation: the AURUM 8 study. Europace (2010) 1.54
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J (2013) 1.53
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol (2006) 1.51
Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up. Heart Rhythm (2005) 1.50
CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest (2011) 1.49
Isolated non-compaction cardiomyopathy. Dtsch Arztebl Int (2010) 1.49
Myocardial systolic and diastolic consequences of left ventricular mechanical dyssynchrony in heart failure with normal left ventricular ejection fraction. Eur Heart J Cardiovasc Imaging (2012) 1.49
Molecular insights into arrhythmogenic right ventricular cardiomyopathy caused by plakophilin-2 missense mutations. Circ Cardiovasc Genet (2012) 1.48
Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: a long-term follow-up. Europace (2011) 1.47
Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens (2014) 1.46
Differential expression of a cutaneous corticotropin-releasing hormone system. Endocrinology (2003) 1.46
Congenital heart defects in adulthood. Dtsch Arztebl Int (2011) 1.45
Spontaneous Brugada electrocardiogram patterns are rare in the German general population: results from the KORA study. Europace (2009) 1.45